<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: <z:chebi fb="0" ids="17230">Homocysteine</z:chebi> (HCY) is a <z:chebi fb="0" ids="26834">sulfur-containing amino acid</z:chebi> considered to be a marker for a relative <z:chebi fb="3" ids="37445">folate</z:chebi> deficiency </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> is a known risk factor for development of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, <z:hpo ids='HP_0000716'>depression</z:hpo>, and possibly some carcinogeneses </plain></SENT>
<SENT sid="2" pm="."><plain>Liver transplant recipients have an increased risk for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> because of a high incidence of <z:hpo ids='HP_0001513'>obesity</z:hpo>, arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, and <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study is to elucidate the determinants for <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> as an additional risk factor in these patients </plain></SENT>
<SENT sid="4" pm="."><plain>MATERIALS AND METHODS: Seventy stable liver transplant recipients, 48 men (mean age, 50+/-11 years) and 22 women (mean age, 52+/-13 years) had their serum <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels tested after orthotopic liver transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>For mainstay immunosuppression, 53 patients were treated with tacrolimus, 10 with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, 3 with <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil, and 4 with <z:chebi fb="0" ids="9168">sirolimus</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Fasting blood samples were obtained and analyzed immediately (within 1 hour) for total serum <z:chebi fb="0" ids="17230">homocysteine</z:chebi> by high-performance liquid chromatography </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In <z:hpo ids='HP_0000001'>all</z:hpo> patients, mean <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels were 22.7+/-14 micromol/L (<z:mpath ids='MPATH_458'>normal</z:mpath> range, 9-15 micromol/L) </plain></SENT>
<SENT sid="8" pm="."><plain>Forty-six patients were found to have <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels&gt;15 micromol/L, and <z:hpo ids='HP_0000001'>all</z:hpo> 70 recipients had <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels&gt;9 micromol/mL </plain></SENT>
<SENT sid="9" pm="."><plain>In our patients, increased <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels correlated well with body mass index and renal function </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="17230">Homocysteine</z:chebi> levels in patients receiving <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> were higher than those in patients receiving tacrolimus (22.3+/-6 vs 17.9+/-12 micromol/L, P&lt;.05) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Overall, <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels are significantly increased in liver transplant recipients </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="17230">Homocysteine</z:chebi> levels correlate well with <z:hpo ids='HP_0001513'>obesity</z:hpo>, renal function, and the particular <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> protocol </plain></SENT>
<SENT sid="13" pm="."><plain>Therefore, a specific treatment for patients after liver transplantation (eg, one with <z:chebi fb="3" ids="37445">folates</z:chebi>) might reduce the risk of complications resulting from <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> </plain></SENT>
</text></document>